A Phase 1 interventional study of AZD0780 and Itraconazole in Dyslipidaemia, sponsored by AstraZeneca. Completed at 1 site in United States. Open to participants aged 18 Years to 75 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-04-27.
Sponsored by AstraZeneca · Phase 1, Interventional, and Other
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 11 studies testing laroprovstat in Dyslipidemias — none open to participants now, 1 under way, 1 of them phase 3. laroprovstat · Dyslipidemias.
Among the 11 studies testing laroprovstat in Dyslipidemias, this one is the 6th largest by enrollment, is one of 4 that started in 2024, is one of 8 in phase 1, and was the 5th registered.
1,249 studies on the registry are indexed under Dyslipidemias; 177 are open to participants now.
Browse Dyslipidemias studies →None of the 11 studies testing laroprovstat in Dyslipidemias is open now. The open studies under Dyslipidemias, anywhere →
No approval found in the FDA or EMA files read. How studies give it is on its page →
Of the 112 Dyslipidemias studies recruiting now, 55 (49%) set no upper age limit and 36 (32%) stop at 75 or younger; 11 take children under 18; 29 take healthy volunteers.
This study: 18 Years to 75 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
11 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 8 · Phase 2 3 · Phase 3 1
First in 2022; this study’s year is marked. 4 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 59 is below the median of 100 across 986 interventional studies indexed under Dyslipidemias.
Median enrollment 59 across the 11 interventional studies. Of the 10 that completed or were terminated, 1 (10%) have results posted.
This tab as a report to print or save as PDF → With an account.
11 of 11 have an industry lead sponsor. The 1 most frequent:
AstraZeneca is the lead sponsor of 3,504 studies on the registry; 274 are open to participants now.
Of its 369 completed or terminated interventional studies of FDA-regulated products, 178 (48%) have results posted.
57 studies in Dyslipidemias by AstraZeneca: 1 open now, 3 under way, 1 of them phase 3. Of 52 finished, 11 (21%) have results posted.
Among the 57 studies in Dyslipidemias by AstraZeneca, this one is the 25th largest by enrollment of the 37 interventional ones that give a count, is one of 5 that started in 2024, is one of 16 in phase 1, and was the 48th registered.
AstraZeneca’s Dyslipidemias studies by the year they started, since 2002.
1 of the studies testing laroprovstat in Dyslipidemias that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06834932Phase 3AstraZenecaA Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of AZD0780 in Participants With Dyslipidaemia | 2027-02-22 |
Add it to your calendar (.ics) → With an account.
Among the 11 studies testing laroprovstat in Dyslipidemias, from their registry updates:
Among AstraZeneca’s 57 in Dyslipidemias:
This tab as a report to print or save as PDF → With an account.
An open-label, fixed sequence study in healthy participants to assess the pharmacokinetics of AZD0780 when administered alone and in combination with itraconazole and carbamazepine, and to assess the pharmacokinetics of midazolam and ethinyl estradiol/levonorgestrel (EE and LNG) when administered alone and in combination with AZD0780.
The purpose of this study is to quantify the effect of itraconazole, a strong CYP3A inhibitor, and carbamazepine, a strong CYP3A inducer, on the PK of AZD0780 in healthy participants. This study will also evaluate AZD0780 as a precipitant of CYP3A4 mediated DDI by examining the PK of midazolam (a CYP3A4 substrate) and EE and LNG (CYP3A4 substrates) alone and in combination with AZD0780 in healthy participants.
The study duration (including screening period) will be approximately 9 to 10 weeks for Part 1, 12 to 14 weeks for Part 2, 6 to 8 weeks for Part 3, and 8 to 10 weeks for Part 4 (optional).
Study visits and treatment:
Number of Participants:
Approximately 78 participants will be enrolled in this study; 18 participants in Part 1 (itraconazole Cohort), 24 participants in Part 2 (carbamazepine Cohort), 18 participants in Part 3 (midazolam Cohort), and 18 Participants in Part 4 (EE and LNG Cohort) (optional).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Females of non-childbearing potential must be confirmed at the Screening Visit by fulfilling one of the following criteria:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
* All participants will receive 2 single doses of dose 1 of AZD0780 and 14 doses of itraconazole, under fed conditions. * This part will consist of Period 1 (AZD0780 administration only), Period 2 (itraconazole administration only), and Period 3 (AZD0780 + itraconazole administration).
Drug: AZD0780 · Drug: Itraconazole
* All participants will receive 2 single doses of dose 1 of AZD0780 and 6 doses of 100 mg, 6 doses of 200 mg, and 40 doses of 300 mg carbamazepine, under fed conditions. * This part will consist of Period 1 (AZD0780 administration only), Period 2 (carbamazepine administration only), and Period 3 (AZD0780 + carbamazepine administration)
Drug: AZD0780 · Drug: Carbamazepine
* All participants will receive 10 single doses of AZD0780 dose 2 and 2 doses of midazolam. On midazolam dosing days, participants will receive midazolam under fasted conditions. * This part will consist of Period 1 (midazolam administration only), Period 2 (AZD0780 administration only), and Period 3 (AZD0780 + midazolam administration).
Drug: AZD0780 · Drug: Midazolam
* All participants will receive 15 single doses of AZD0780 dose 2 and 2 doses of EE and LNG. On EE and LNG dosing days, participants will receive EE and LNG under fasted conditions. * This part will consist of Period 1 (EE and LNG administration only), Period 2 (AZD0780 administration only), and Period 3 (AZD0780 + EE and LNG administration).
Drug: AZD0780 · Drug: Ethinyl estradiol/levonorgestrel
Dose 1 and Dose 2
* Period 2 (itraconazole administration only). * Period 3 (AZD0780 + itraconazole administration).
* Period 2 (carbamazepine administration only). * Period 3 (AZD0780 + carbamazepine administration only).
* Period 1 (midazolam administration only). * Period 3 (AZD0780 + midazolam administration).
* Period 1 (EE and LNG administration only). * Period 3 (AZD0780 + EE and LNG administration).
AUCinf (Area under concentration-time curve from time 0 to infinity)
To describe the PK of AZD0780 when administered alone and in combination with itraconazole and carbamazepine.
Time frame: Period 1 (Day 1 to 11 Cohort 1 and Cohort 2) and Period 3 (Day 14-24 Part 1 and Day 27-37 Part 2)
AUClast (Area under concentration curve from time 0 to the last quantifiable concentration)
To describe the PK of AZD0780 when administered alone and in combination with itraconazole and carbamazepine.
Time frame: Period 1 (Day 1 to 11 Cohort 1 and Cohort 2) and Period 3 (Day 14-24 Part 1 and Day 27-37 Part 2)
Cmax (Maximum observed drug concentration)
To describe the PK of AZD0780 when administered alone and in combination with itraconazole and carbamazepine.
Time frame: Period 1 (Day 1 to 11 Cohort 1 and Cohort 2) and Period 3 (Day 14-24 Part 1 and Day 27-37 Part 2)
AUCinf
To assess the effect of AZD0780 on the PK of midazolam (Part 3) and EE and LNG (Part 4).
Time frame: Period 1 (Day 1 to 2 Part 3 and Day 1 to 7 Part 4) and Period 3 (Day 11-12 Part 3 and Day 16 to 22 Part 4)
AUClast
To assess the effect of AZD0780 on the PK of midazolam (Part 3) and EE and LNG (Part 4).
Time frame: Period 1 (Day 1 to 2 Part 3 and Day 1 to 7 Part 4) and Period 3 (Day 11-12 Part 3 and Day 16 to 22 Part 4)
Cmax
To assess the effect of AZD0780 on the PK of midazolam (Part 3) and EE and LNG (Part 4).
Time frame: Period 1 (Day 1 to 2 Part 3 and Day 1 to 7 Part 4) and Period 3 (Day 11-12 Part 3 and Day 16 to 22 Part 4)
CL/F (Apparent total body clearance)
To describe the PK of AZD0780 when administered alone, in combination with itraconazole or in combination with carbamazepine.
Time frame: Period 1 (Day 1 to 11 Cohort 1 and Cohort 2) and Period 3 (Day 14-24 Part 1 and Day 27-37 Part 2)
t½λz (Terminal elimination half-life)
To describe the PK of AZD0780 when administered alone, in combination with itraconazole or in combination with carbamazepine.
Time frame: Period 1 (Day 1 to 11 Cohort 1 and Cohort 2) and Period 3 (Day 14-24 Part 1 and Day 27-37 Part 2)
tmax (Time to reach maximum observed concentration)
To describe the PK of AZD0780 when administered alone, in combination with itraconazole or in combination with carbamazepine.
Time frame: Period 1 (Day 1 to 11 Cohort 1 and Cohort 2) and Period 3 (Day 14-24 Part 1 and Day 27-37 Part 2)
Vz/F (Apparent volume of distribution based on the terminal phase)
To describe the PK of AZD0780 when administered alone, in combination with itraconazole or in combination with carbamazepine.
Time frame: Period 1 (Day 1 to 11 Cohort 1 and Cohort 2) and Period 3 (Day 14-24 Part 1 and Day 27-37 Part 2)
Number of participants with Adverse Events and Serious Adverse Events (AEs and SAEs)
To assess the safety and tolerability of AZD0780 when administered alone and in combination with itraconazole, carbamazepine, midazolam and EE and LNG.
Time frame: From Baseline until Follow-up Visit (7 to 14 days post-discharge)
Number of participants with treatment emergent abnormal ECGs
To assess the safety and tolerability of AZD0780 when administered alone and in combination with itraconazole, carbamazepine, midazolam and EE and LNG.
Time frame: From Baseline until Follow-up Visit (7 to 14 days post-discharge)
Vital signs and laboratory test results
To assess the safety and tolerability of AZD0780 when administered alone and in combination with itraconazole, carbamazepine, midazolam and EE and LNG.
Time frame: From Baseline until Follow-up Visit (7 to 14 days post-discharge)
CL/F
To describe the PK of midazolam (Part 3) and EE and LNG (Part 4) when administered alone and in combination with AZD0780.
Time frame: Period 1 (Day 1 to 2 Part 3 and Day 1 to 7 Part 4) and Period 3 (Day 11-12 Part 3 and Day 16 to 22 Part 4)
t½λz
To describe the PK of midazolam (Part 3) and EE and LNG (Part 4) when administered alone and in combination with AZD0780.
Time frame: Period 1 (Day 1 to 2 Part 3 and Day 1 to 7 Part 4) and Period 3 (Day 11-12 Part 3 and Day 16 to 22 Part 4)
tmax
TTo describe the PK of midazolam (Part 3) and EE and LNG (Part 4) when administered alone and in combination with AZD0780.
Time frame: Period 1 (Day 1 to 2 Part 3 and Day 1 to 7 Part 4) and Period 3 (Day 11-12 Part 3 and Day 16 to 22 Part 4)
Vz/F
To describe the PK of midazolam (Part 3) and EE and LNG (Part 4) when administered alone and in combination with AZD0780.
Time frame: Period 1 (Day 1 to 2 Part 3 and Day 1 to 7 Part 4) and Period 3 (Day 11-12 Part 3 and Day 16 to 22 Part 4)
Ran from Sep 2024 to primary completion in Feb 2025, 4 months.
Of 77 industry-sponsored phase 1 interventional studies under Dyslipidemias, half reached primary completion within 2 months of starting (the median), counting those still running; a quarter within 1 and three quarters within 8. This study's 4 months is above that.
Counting every sponsor, half of 83 studies reached it within 2 months; a quarter within 1 and three quarters within 10.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Laroprovstat